Apyx Medical (APYX) Receivables (2010 - 2026)

Apyx Medical (APYX) has reported Receivables for 17 consecutive years, with $13.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 21.03% year-over-year to $13.6 million; the trailing twelve-month figure through Jun 2026 stood at $13.6 million (up 21.03% YoY), and the FY2025 full-year result was $16.8 million, up 8.37% from the prior year.
• Receivables rose to $13.6 million in Q2 2026 per APYX's latest filing, from $12.8 million in the prior quarter.
• Across five years, Receivables topped out at $16.8 million in Q4 2025 and bottomed at $600000.0 in Q4 2023.
• Historically, Receivables has averaged $11.8 million across 5 years, with a median of $12.5 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Receivables plunged 94.39% in 2023, then jumped 2480.0% in 2024.
• Over 5 years, Receivables stood at $10.7 million in 2022, then slumped by 94.39% to $600000.0 in 2023, then surged by 2480.0% to $15.5 million in 2024, then increased by 8.37% to $16.8 million in 2025, then retreated by 18.85% to $13.6 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $13.6 million, $12.8 million, and $16.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.